Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This program collects genetic and health information to help doctors choose the right medications for patients.
This study wants to understand how genes can affect how the body responds to medicines. This information will help us determine whether changing your medicine can make you healthier and improve your life. We will study your medical history for the last year and the next five years after you join the study.
study goals include:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Polypharmacy | Patients taking many medications or medications with severe side effects |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Frequency and nature of ADRs on the Naranjo Scale | Patients will be referred to the Texas A&M Interprofessional Pharmacogenomics Clinic (IPGx) by their primary care physicians. A physician or ambulatory pharmacist in the IPGx clinic or Family Care Clinic will obtain a complete medical history, physical examination, and validate the patient's current concomitant medication list at the IPGx during the office visit. Patient medical information would be input into the CSN, which functions as a computable EHR medical record analysis, evaluation of polypharmacy status, and monitoring of Adverse Drug Reactions using the Naranjo Scale questionnaire will be conducted for the duration of the study. | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Serum/plasma drug concentrations | Patients will be referred to the Texas A&M Interprofessional Pharmacogenomics Clinic (IPGx) by their primary care physicians for an evaluation of pharmacokinetic and pharmacodynamic (PK/PD) assessments. For drug level measurement, urine samples will be collected using provided kits and shipped to the contracted laboratory via FedEx in biosafety shipping containers. |
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacogenomic genotype with corresponding ADR phenotype | Patients will be referred to the Texas A&M Interprofessional Pharmacogenomics Clinic (IPGx) by their primary care physicians to evaluate genotyping and ADR. Clinical staff will obtain a buccal swab to collect DNA for a pharmacogenomic evaluation pursuant to the sample collection kits from the CLIA lab, which will occur at the start of the study period. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Texas A&M Health clinical programs.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Kenneth S Ramos, MD, PhD | Contact | (713) 677-7440 | kramos@tamu.edu | |
| Rick Silva, PhD | Contact | (713) 677-7422 | ricksilva@tamu.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Texas A&M Family Care | Recruiting | Bryan | Texas | 77802 | United States |
All collected IPD deidentified
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D009369 | Neoplasms |
| D006331 | Heart Diseases |
| D029424 | Pulmonary Disease, Chronic Obstructive |
| D064420 | Drug-Related Side Effects and Adverse Reactions |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
blood, urine, and cheek cells
| 5 years |
| 5 years |
| Drug-drug interactions, drug gene interactions, drug-drug-gene interactions | An assessment at the IPGx begins with a consultation by a pharmacist or physician. They will evaluate the medications and other drugs the patient is currently using, identifying any potential issues related to toxicity, drug interactions, or side effects that may be relevant to the patient's clinical presentation. | 5 years |
| D002318 | Cardiovascular Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D064419 | Chemically-Induced Disorders |